NEW YORK, May 2, 2023 /PRNewswire/ -- The orphan drugs market size is forecast to increase by USD 170.8 billion from 2022 to 2027, at a CAGR of 14.02%, according to the recent market study by Technavio. The growth of the market will be driven by the robust pipeline and recent drug approvals, the rising incidence of rare diseases, and the availability of incentives for orphan drug development. Charts & data tables about market and segment sizes for a historic period (2017-2021) and forecast period (2023-2027) have been covered in this report. Download The Sample Report
Vendor Analysis
The global orphan drugs market is fragmented, with numerous players spread across various sizes and offerings. This large spread, combined with the privileges given by regulatory bodies, huge unmet needs, complex pathogenesis of rare diseases, and strong industry growth rate, has made the competition high. Hence, the threat of rivalry was high in 2022, and it is expected to remain the same during the forecast period. Some of the key vendors covered in the report include:
- Alnylam Pharmaceuticals Inc. - The company offers orphan drugs such as ALN-AT3 RNAi therapeutic.
- Astellas Pharma Inc. - The company offers orphan drugs such as Gilteritinib and isavuconazole.
- AstraZeneca Plc - The company offers orphan drugs such as Tezepelumab, Enhertu, and Saracatinib.
- bluebird bio Inc. - The company offers orphan drugs such as Betibeglogene Autotemcel.
- Bristol Myers Squibb Co.
- CSL Ltd.
- F. Hoffmann La Roche Ltd.
- Gilead Sciences Inc.
- GlaxoSmithKline Plc
- Ipsen Pharma
- Johnson and Johnson Services Inc.
- Merck and Co. Inc.
- Novartis AG
- Novo Nordisk AS
- Pfizer Inc.
Why Buy?
- Add credibility to strategy
- Analyzes competitor's offerings
- Get a holistic view of the market
Grow your profit margin with Technavio - Buy the Report
Key Benefits for Industry Players & Stakeholders –
- The report offers information on the criticality of vendor inputs, including R&D, CAPEX, and technology.
- It also provides detailed analyses of the market's competitive landscape and vendors' product offerings.
- The report also provides a qualitative and quantitative analysis of vendors to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.
Get a holistic overview of the orphan drugs market by industry experts to evaluate and develop growth strategies. Download the Sample
Market Segmentation:
The market is segmented by distribution channel (hospital pharmacy, specialty pharmacy, retail pharmacy, and others), product (biologics and non-biologics), and geography (North America, Europe, Asia, and Rest of World (ROW).
- The market growth in the hospital pharmacy segment will be significant over the forecast period. Hospital pharmacy is the most accessible source for orphan drugs. Hospital pharmacy helps in creating a specific dosing regimen that is individualized for each patient. It allows doctors and other health care professionals to make drug-based decisions and help patients understand their medications. Such factors drive the growth of the segment.
- North America will account for 40% of the market growth during the forecast period. The growth of the regional market can be attributed to various factors, including new drug approvals, growing diagnosis of rare diseases, availability of reimbursement schemes, the high premium price of orphan drugs, and the strong presence of key vendors. The high prevalence of rare diseases and advancements in the treatment of orphan diseases are other factors driving the growth of the orphan drugs market in North America.
Market Dynamics:
Key DRIVERS:
- Rising incidence of rare diseases
- Robust pipeline and recent drug approvals
- Availability of incentives for orphan drug development
The prevalence of rare diseases such as inherited genetic disorders, rare types of cancer, tropical infectious diseases, and neurodegenerative diseases is increasing worldwide. For instance, according to the National institutes of health (NIH), about 400 million people worldwide suffer from rare diseases. This is greater than the number of people affected by cancer and AIDS combined. Despite the high prevalence of rare diseases, the market still lacks proper diagnostic methods for many inherited rare diseases. This has led many diagnostic and pharmaceutical companies to do extensive research on rare diseases. Such studies have led to extensive exposure to the usage of orphan products, which is driving the growth of the market.
Major Trends:
- Strategic focus on alliances, partnerships, and M&As
- Emergence of combination therapies and novel targets
- Rising demand for genetic tests and protein biomarkers
The market has witnessed increased consolidation between vendors over recent years. Vendors are adopting strategies such as partnerships and strategic alliances to extend their reach to a larger geographical area, expand product portfolios, and earn a higher ROI. Vendors are also adopting these strategies to overcome the imminent patent expiration as well as the need to replenish the robust pipeline. In addition, vendors are adopting multiple approaches for effective strategic collaborations to offset the challenges associated with manufacturing processes and translational biology. For instance, several gene therapy-focused vendors are actively involved in collaborating to support commercially viable products due to the uncertainties in the market. Such developments among vendors will positively influence the market growth over the forecast period.
Key Challenges:
- Delay in diagnosis
- Risks associated with clinical development of novel orphan drugs
- Challenges associated with pricing and reimbursements for orphan drugs
Timely diagnosis is essential in improving the care of patients with rare diseases as they are often difficult to diagnose. However, the diagnosis of many rare diseases has been limited by costly testing, lack of awareness, and their asymptomatic nature. This leads to delays in diagnosis, which may result in severe, irreversible, and debilitating disease progression. Delayed diagnosis also increases the number of hospital visits and makes patients and caregivers feel frustrated and scared. Such challenges restrict the growth of the market.
Gain instant access to 17,000+ market research reports, Subscribe to our Basic Plan billed annually at USD 5000.
Technavio's SUBSCRIPTION platform
What are the key data covered in this orphan drugs market report?
- CAGR of the market during the forecast period
- Detailed information on factors that will drive the growth of the orphan drugs market between 2023 and 2027
- Precise estimation of the size of the orphan drugs market and its contribution to the parent market
- Accurate predictions about upcoming trends and changes in consumer behavior
- Growth of the orphan drugs market across North America, Europe, Asia, and Rest of World (ROW)
- A thorough analysis of the market's competitive landscape and detailed information about vendors
- Comprehensive analysis of factors that will challenge the growth of orphan drugs market vendors
Related Reports:
The cardiovascular therapeutics market size is estimated to grow at a CAGR of 7.32% between 2022 and 2027. The cardiovascular therapeutics market size is forecast to increase by USD 37.77 billion. The market is segmented by type (antithrombotic drugs, hypolipidemic drugs, and others), distribution channel (hospital pharmacy, retail pharmacy, and online pharmacy), and geography (Asia, North America, Europe, and Rest of World).
The pulmonary arterial hypertension (PAH) drugs market size is estimated to grow at a CAGR of 6.62% between 2022 and 2027. The pulmonary arterial hypertension drugs market size is forecast to increase by USD 2,080.07 million. The market is segmented by route of administration (oral, injectable, and inhalation), action mechanism (prostacyclin analogs, endothelin receptor antagonists (ERAS), phosphodiesterase (PDE) inhibitors, and soluble guanylate cyclase stimulators (SGCSS)), and geography (North America, Europe, Asia, and Rest of World (ROW)).
Orphan Drugs Market Scope |
|
Report Coverage |
Details |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 14.02% |
Market growth 2023-2027 |
USD 170.8 billion |
Market structure |
Fragmented |
YoY growth 2022-2023 (%) |
13.24 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 40% |
Key countries |
US, Canada, UK, Germany, and China |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
AbbVie Inc., Alnylam Pharmaceuticals Inc., Astellas Pharma Inc., AstraZeneca Plc, bluebird bio Inc., Bristol Myers Squibb Co., CSL Ltd., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Ipsen Pharma, Johnson and Johnson Services Inc., Merck and Co. Inc., Novartis AG, Novo Nordisk AS, Pfizer Inc., Ractigen Therapeutics, Sanofi SA, Takeda Pharmaceutical Co. Ltd., and Vertex Pharmaceuticals Inc. |
Market dynamics |
Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Browse through Technavio's Health Care Market Reports
Table of contents:
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Distribution Channel
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Product
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 13: Market segments
- 3.3 Market size 2022
- 3.4 Market outlook: Forecast for 2022-2027
- Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ billion)
- Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ billion)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
4 Historic Market Size
- 4.1 Global orphan drugs market 2017 - 2021
- Exhibit 18: Historic Market Size – Data Table on Global orphan drugs market 2017 - 2021 ($ billion)
- 4.2 Distributed Channel Segment Analysis 2017 - 2021
- Exhibit 19: Historic Market Size – Distributed Channel Segment 2017 - 2021 ($ billion)
- 4.3 Product Segment Analysis 2017 - 2021
- Exhibit 20: Historic Market Size – Product Segment 2017 - 2021 ($ billion)
- 4.4 Geography Segment Analysis 2017 - 2021
- Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ billion)
- 4.5 Country Segment Analysis 2017 - 2021
- Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ billion)
5 Five Forces Analysis
- 5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
- 5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
- 5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
- 5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
- 5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
- 5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
- 5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2022 and 2027
6 Market Segmentation by Distribution Channel
- 6.1 Market segments
- Exhibit 30: Chart on Distribution Channel - Market share 2022-2027 (%)
- Exhibit 31: Data Table on Distribution Channel - Market share 2022-2027 (%)
- 6.2 Comparison by Distribution Channel
- Exhibit 32: Chart on Comparison by Distribution Channel
- Exhibit 33: Data Table on Comparison by Distribution Channel
- 6.3 Hospital pharmacy - Market size and forecast 2022-2027
- Exhibit 34: Chart on Hospital pharmacy - Market size and forecast 2022-2027 ($ billion)
- Exhibit 35: Data Table on Hospital pharmacy - Market size and forecast 2022-2027 ($ billion)
- Exhibit 36: Chart on Hospital pharmacy - Year-over-year growth 2022-2027 (%)
- Exhibit 37: Data Table on Hospital pharmacy - Year-over-year growth 2022-2027 (%)
- 6.4 Specialty pharmacy - Market size and forecast 2022-2027
- Exhibit 38: Chart on Specialty pharmacy - Market size and forecast 2022-2027 ($ billion)
- Exhibit 39: Data Table on Specialty pharmacy - Market size and forecast 2022-2027 ($ billion)
- Exhibit 40: Chart on Specialty pharmacy - Year-over-year growth 2022-2027 (%)
- Exhibit 41: Data Table on Specialty pharmacy - Year-over-year growth 2022-2027 (%)
- 6.5 Retail pharmacy - Market size and forecast 2022-2027
- Exhibit 42: Chart on Retail pharmacy - Market size and forecast 2022-2027 ($ billion)
- Exhibit 43: Data Table on Retail pharmacy - Market size and forecast 2022-2027 ($ billion)
- Exhibit 44: Chart on Retail pharmacy - Year-over-year growth 2022-2027 (%)
- Exhibit 45: Data Table on Retail pharmacy - Year-over-year growth 2022-2027 (%)
- 6.6 Others - Market size and forecast 2022-2027
- Exhibit 46: Chart on Others - Market size and forecast 2022-2027 ($ billion)
- Exhibit 47: Data Table on Others - Market size and forecast 2022-2027 ($ billion)
- Exhibit 48: Chart on Others - Year-over-year growth 2022-2027 (%)
- Exhibit 49: Data Table on Others - Year-over-year growth 2022-2027 (%)
- 6.7 Market opportunity by Distribution Channel
- Exhibit 50: Market opportunity by Distribution Channel ($ billion)
- Exhibit 51: Data Table on Market opportunity by Distribution Channel ($ billion)
7 Market Segmentation by Product
- 7.1 Market segments
- Exhibit 52: Chart on Product - Market share 2022-2027 (%)
- Exhibit 53: Data Table on Product - Market share 2022-2027 (%)
- 7.2 Comparison by Product
- Exhibit 54: Chart on Comparison by Product
- Exhibit 55: Data Table on Comparison by Product
- 7.3 Biologics - Market size and forecast 2022-2027
- Exhibit 56: Chart on Biologics - Market size and forecast 2022-2027 ($ billion)
- Exhibit 57: Data Table on Biologics - Market size and forecast 2022-2027 ($ billion)
- Exhibit 58: Chart on Biologics - Year-over-year growth 2022-2027 (%)
- Exhibit 59: Data Table on Biologics - Year-over-year growth 2022-2027 (%)
- 7.4 Non-biologics - Market size and forecast 2022-2027
- Exhibit 60: Chart on Non-biologics - Market size and forecast 2022-2027 ($ billion)
- Exhibit 61: Data Table on Non-biologics - Market size and forecast 2022-2027 ($ billion)
- Exhibit 62: Chart on Non-biologics - Year-over-year growth 2022-2027 (%)
- Exhibit 63: Data Table on Non-biologics - Year-over-year growth 2022-2027 (%)
- 7.5 Market opportunity by Product
- Exhibit 64: Market opportunity by Product ($ billion)
- Exhibit 65: Data Table on Market opportunity by Product ($ billion)
8 Customer Landscape
- 8.1 Customer landscape overview
- Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
- 9.1 Geographic segmentation
- Exhibit 67: Chart on Market share by geography 2022-2027 (%)
- Exhibit 68: Data Table on Market share by geography 2022-2027 (%)
- 9.2 Geographic comparison
- Exhibit 69: Chart on Geographic comparison
- Exhibit 70: Data Table on Geographic comparison
- 9.3 North America - Market size and forecast 2022-2027
- Exhibit 71: Chart on North America - Market size and forecast 2022-2027 ($ billion)
- Exhibit 72: Data Table on North America - Market size and forecast 2022-2027 ($ billion)
- Exhibit 73: Chart on North America - Year-over-year growth 2022-2027 (%)
- Exhibit 74: Data Table on North America - Year-over-year growth 2022-2027 (%)
- 9.4 Europe - Market size and forecast 2022-2027
- Exhibit 75: Chart on Europe - Market size and forecast 2022-2027 ($ billion)
- Exhibit 76: Data Table on Europe - Market size and forecast 2022-2027 ($ billion)
- Exhibit 77: Chart on Europe - Year-over-year growth 2022-2027 (%)
- Exhibit 78: Data Table on Europe - Year-over-year growth 2022-2027 (%)
- 9.5 Asia - Market size and forecast 2022-2027
- Exhibit 79: Chart on Asia - Market size and forecast 2022-2027 ($ billion)
- Exhibit 80: Data Table on Asia - Market size and forecast 2022-2027 ($ billion)
- Exhibit 81: Chart on Asia - Year-over-year growth 2022-2027 (%)
- Exhibit 82: Data Table on Asia - Year-over-year growth 2022-2027 (%)
- 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
- Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
- Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
- Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
- Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
- 9.7 US - Market size and forecast 2022-2027
- Exhibit 87: Chart on US - Market size and forecast 2022-2027 ($ billion)
- Exhibit 88: Data Table on US - Market size and forecast 2022-2027 ($ billion)
- Exhibit 89: Chart on US - Year-over-year growth 2022-2027 (%)
- Exhibit 90: Data Table on US - Year-over-year growth 2022-2027 (%)
- 9.8 UK - Market size and forecast 2022-2027
- Exhibit 91: Chart on UK - Market size and forecast 2022-2027 ($ billion)
- Exhibit 92: Data Table on UK - Market size and forecast 2022-2027 ($ billion)
- Exhibit 93: Chart on UK - Year-over-year growth 2022-2027 (%)
- Exhibit 94: Data Table on UK - Year-over-year growth 2022-2027 (%)
- 9.9 Canada - Market size and forecast 2022-2027
- Exhibit 95: Chart on Canada - Market size and forecast 2022-2027 ($ billion)
- Exhibit 96: Data Table on Canada - Market size and forecast 2022-2027 ($ billion)
- Exhibit 97: Chart on Canada - Year-over-year growth 2022-2027 (%)
- Exhibit 98: Data Table on Canada - Year-over-year growth 2022-2027 (%)
- 9.10 China - Market size and forecast 2022-2027
- Exhibit 99: Chart on China - Market size and forecast 2022-2027 ($ billion)
- Exhibit 100: Data Table on China - Market size and forecast 2022-2027 ($ billion)
- Exhibit 101: Chart on China - Year-over-year growth 2022-2027 (%)
- Exhibit 102: Data Table on China - Year-over-year growth 2022-2027 (%)
- 9.11 Germany - Market size and forecast 2022-2027
- Exhibit 103: Chart on Germany - Market size and forecast 2022-2027 ($ billion)
- Exhibit 104: Data Table on Germany - Market size and forecast 2022-2027 ($ billion)
- Exhibit 105: Chart on Germany - Year-over-year growth 2022-2027 (%)
- Exhibit 106: Data Table on Germany - Year-over-year growth 2022-2027 (%)
- 9.12 Market opportunity by geography
- Exhibit 107: Market opportunity by geography ($ billion)
- Exhibit 108: Data Tables on Market opportunity by geography ($ billion)
10 Drivers, Challenges, and Trends
- 10.1 Market drivers
- 10.2 Market challenges
- 10.3 Impact of drivers and challenges
- Exhibit 109: Impact of drivers and challenges in 2022 and 2027
- 10.4 Market trends
11 Vendor Landscape
- 11.1 Overview
- 11.2 Vendor landscape
- Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
- 11.3 Landscape disruption
- Exhibit 111: Overview on factors of disruption
- 11.4 Industry risks
- Exhibit 112: Impact of key risks on business
12 Vendor Analysis
- 12.1 Vendors covered
- Exhibit 113: Vendors covered
- 12.2 Market positioning of vendors
- Exhibit 114: Matrix on vendor position and classification
- 12.3 AbbVie Inc.
- Exhibit 115: AbbVie Inc. - Overview
- Exhibit 116: AbbVie Inc. - Product / Service
- Exhibit 117: AbbVie Inc. - Key news
- Exhibit 118: AbbVie Inc. - Key offerings
- 12.4 Alnylam Pharmaceuticals Inc.
- Exhibit 119: Alnylam Pharmaceuticals Inc. - Overview
- Exhibit 120: Alnylam Pharmaceuticals Inc. - Product / Service
- Exhibit 121: Alnylam Pharmaceuticals Inc. - Key news
- Exhibit 122: Alnylam Pharmaceuticals Inc. - Key offerings
- 12.5 Astellas Pharma Inc.
- Exhibit 123: Astellas Pharma Inc. - Overview
- Exhibit 124: Astellas Pharma Inc. - Product / Service
- Exhibit 125: Astellas Pharma Inc. - Key news
- Exhibit 126: Astellas Pharma Inc. - Key offerings
- 12.6 AstraZeneca Plc
- Exhibit 127: AstraZeneca Plc - Overview
- Exhibit 128: AstraZeneca Plc - Product / Service
- Exhibit 129: AstraZeneca Plc - Key news
- Exhibit 130: AstraZeneca Plc - Key offerings
- 12.7 bluebird bio Inc.
- Exhibit 131: bluebird bio Inc. - Overview
- Exhibit 132: bluebird bio Inc. - Product / Service
- Exhibit 133: bluebird bio Inc. - Key offerings
- 12.8 Bristol Myers Squibb Co.
- Exhibit 134: Bristol Myers Squibb Co. - Overview
- Exhibit 135: Bristol Myers Squibb Co. - Product / Service
- Exhibit 136: Bristol Myers Squibb Co. - Key news
- Exhibit 137: Bristol Myers Squibb Co. - Key offerings
- 12.9 CSL Ltd.
- Exhibit 138: CSL Ltd. - Overview
- Exhibit 139: CSL Ltd. - Business segments
- Exhibit 140: CSL Ltd. - Key news
- Exhibit 141: CSL Ltd. - Key offerings
- Exhibit 142: CSL Ltd. - Segment focus
- 12.10 F. Hoffmann La Roche Ltd.
- Exhibit 143: F. Hoffmann La Roche Ltd. - Overview
- Exhibit 144: F. Hoffmann La Roche Ltd. - Business segments
- Exhibit 145: F. Hoffmann La Roche Ltd. - Key news
- Exhibit 146: F. Hoffmann La Roche Ltd. - Key offerings
- Exhibit 147: F. Hoffmann La Roche Ltd. - Segment focus
- 12.11 Gilead Sciences Inc.
- Exhibit 148: Gilead Sciences Inc. - Overview
- Exhibit 149: Gilead Sciences Inc. - Product / Service
- Exhibit 150: Gilead Sciences Inc. - Key news
- Exhibit 151: Gilead Sciences Inc. - Key offerings
- 12.12 GlaxoSmithKline Plc
- Exhibit 152: GlaxoSmithKline Plc - Overview
- Exhibit 153: GlaxoSmithKline Plc - Business segments
- Exhibit 154: GlaxoSmithKline Plc - Key news
- Exhibit 155: GlaxoSmithKline Plc - Key offerings
- Exhibit 156: GlaxoSmithKline Plc - Segment focus
- 12.13 Ipsen Pharma
- Exhibit 157: Ipsen Pharma - Overview
- Exhibit 158: Ipsen Pharma - Business segments
- Exhibit 159: Ipsen Pharma - Key offerings
- Exhibit 160: Ipsen Pharma - Segment focus
- 12.14 Johnson and Johnson Services Inc.
- Exhibit 161: Johnson and Johnson Services Inc. - Overview
- Exhibit 162: Johnson and Johnson Services Inc. - Business segments
- Exhibit 163: Johnson and Johnson Services Inc. - Key news
- Exhibit 164: Johnson and Johnson Services Inc. - Key offerings
- Exhibit 165: Johnson and Johnson Services Inc. - Segment focus
- 12.15 Merck and Co. Inc.
- Exhibit 166: Merck and Co. Inc. - Overview
- Exhibit 167: Merck and Co. Inc. - Business segments
- Exhibit 168: Merck and Co. Inc. - Key news
- Exhibit 169: Merck and Co. Inc. - Key offerings
- Exhibit 170: Merck and Co. Inc. - Segment focus
- 12.16 Novartis AG
- Exhibit 171: Novartis AG - Overview
- Exhibit 172: Novartis AG - Business segments
- Exhibit 173: Novartis AG - Key offerings
- Exhibit 174: Novartis AG - Segment focus
- 12.17 Ractigen Therapeutics
- Exhibit 175: Ractigen Therapeutics - Overview
- Exhibit 176: Ractigen Therapeutics - Product / Service
- Exhibit 177: Ractigen Therapeutics - Key offerings
13 Appendix
- 13.1 Scope of the report
- 13.2 Inclusions and exclusions checklist
- Exhibit 178: Inclusions checklist
- Exhibit 179: Exclusions checklist
- 13.3 Currency conversion rates for US$
- Exhibit 180: Currency conversion rates for US$
- 13.4 Research methodology
- Exhibit 181: Research methodology
- Exhibit 182: Validation techniques employed for market sizing
- Exhibit 183: Information sources
- 13.5 List of abbreviations
- Exhibit 184: List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
Share this article